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A B S T R A C T
Ferritin proteins are taking center stage as smart nanocarriers for drug delivery due to their hollow cage-like
structures and their unique 24-meric assembly. Among all ferritins, the chimeric Archaeoglobus ferritin (HumFt)
is able assemble/disassemble varying the ionic strength of the medium while recognizing human TfR1 receptor
overexpressed in cancer cells. In this paper we present a highly efficient, large scale purification protocol mainly
based on crossflow ultrafiltration, starting from fermented bacterial paste. This procedure allows one to obtain
about 2 g of purified protein starting from 100 g of fermented bacterial paste. The current procedure can easily
remove contaminant proteins as well as DNA molecules in the absence of expensive and time consuming
chromatographic steps.
1. Introduction
Ferritins are members of a superfamily of iron storage/detoxifica-
tion proteins, found in all living systems with the exception of yeasts
[1,2]. From a structural point of view, they consist of 24 subunits that
assemble to form a spherical nanocage with an external diameter of
about 12 nm and an internal diameter of 8 nm. Each monomer consists
of a bundle of four antiparallel α-helices (A–D) plus a short fifth helix
(E) pointing inside the protein cavity, roughly at 60° to the principal
helix bundle. An unfolded loop traverses the full length of the helical
bundle and connects the helices B and C [3,4]. Ferritin nanocages are
able to self-assemble in a 24-mer protein shell and the dimers are the
first intermediate in this pathway [5,6].
Mammalian ferritins are typically made of two types of subunits,
namely H (havy, 21 kDa) and L (light, 19 kDa), whose proportion is
different in different tissues. H chain subunit is able to oxidize Fe(II) to
Fe(III), while the L one lacks catalytic activity but holds a micro-
environment that facilitates iron nucleation and mineralization [7,8].
Ferritin nanocages can load up to 4500 iron atoms in the form of highly
insoluble Fe(OH)3(H2O)3.
Despite significant differences in the primary sequences, mamma-
lian and bacterial ferritins share similar structures and properties [9].
However, significant differences in quaternary structure and assembly
have been described for Archaeoglobus fulgidus ferritin (AfFtn) [10]. In
fact, whereas ferritins display a “closed” octahedral (4-3-2) archi-
tecture, the AfFtn exhibits a tetrahedral (2–3) symmetry resulting in the
appearance of four large triangular pores (~45 Å wide) in the protein
shell. This “open” quaternary structure is unique among all other
known ferritins. Another typical feature of AfFtn is the ability to as-
semble/disassemble depending on the salt concentration. The protein is
fully assembled at high ionic strength (0.5M NaCl) or in the presence of
divalent cations (10mM MgCl2) [11].
Due to their self-assembly properties, hollow cavity, mono-
dispersity, thermal stability (up to 80 °C), pH stability, biocompat-
ibility, ferritins are taking center stage as smart nanocarriers for drug
delivery, especially for the treatment of cancer cells [12]. This kind of
cells overexpress TfR1 receptor, that is involved in transferrin uptake,
but is also able to bind and internalize circulating ferritin [13,14]. In
the last years, in fact, many research groups have exploited the po-
tential of ferritin by loading it with conventional anticancer drugs,
contrast agents, therapeutic proteins and/or incorporating various
cargoes and targeting moieties on the surface [15–18]. Drug en-
capsulation can be easily achieved in vitro by disassembling the 24-mer
by changing the pH, while the reassembly of the shell occurs sponta-
neously when the pH is restored [19]. However, a significant loss of
protein is a typical drawback of this kind of procedure and cargoes
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could be quite unstable upon pH changing. Archaeglobus ferritin might
overcome these problems as it is able to assemble/disassemble at
neutral pH values just changing the ionic strength of the medium [11].
AfFtn has been engineered by grafting H-ferritin BC loop resulting in a
chimeric protein (humanized ferritin, HumFt) being able to recognize
TfR1 receptor and to be consequently internalized within the cells [20].
Thus, among all known ferritins, HumFt can be considered as a unique
tool for targeted delivery of therapeutics and contrast agents. Con-
sidering the large number of potential applications of this new chimeric
construct, it is of a paramount importance to develop a purification
protocol that allows to obtain a large amount of highly purified protein.
In this paper, we develop a highly efficient, large scale, chromato-
graphy-free purification protocol mainly based on crossflow ultra-
filtration, starting from fermented bacterial paste. Ultrafiltration is one
of the most used form of membrane base tangential flow filtration and
is used to separate proteins form buffer components, for buffer ex-
change, desalting or concentration. It is gaining great attention, espe-
cially for large scale protein purification, due to its outstanding tech-
nical and economic advantages [21,22].
The purification method we set up has the advantage to easily
eliminate contaminant proteins as well as DNA molecules, that usually
co-purify with ferritins affecting the association/dissociation equili-
brium. This aspect is of great importance in view of the therapeutic
applications of HumFt as a nanocarrier.
2. Materials and methods
2.1. Bacterial cell growth
The synthetic gene encoding humanized ferritin (humft) optimized
for the expression in E. coli cells was subcloned into a pET30a plasmid
(Novagen) between NdeI/HindIII restriction sites. A stop codon was
added before the HindIII recognition sequence. The recombinant ex-
pression vector pET30a-humft was transformed into BL21(DE3) com-
petent cells. Protein expression was set up optimizing IPTG con-
centration, time and temperature of induction. IPTG was tested at three
different concentrations (0.1, 0.5 and 1mM); induction was carried out
for 4, 8 and 16 h at 25 and 37 °C. Customized large scale protein pro-
duction was performed by GeneScript under high density fermentative
condition (induction with 0.5mM IPTG at 25 °C for 16 h).
2.2. Purification strategies
100 g of bacterial paste were resuspended in 1 L of 20mM HEPES
buffer containing 50mM MgCl2 and four cOmplete™ Protease Inhibitor
Cocktail Tablets (Roche). Cells were disrupted by sonication and the
soluble fraction was treated with 20% (NH4)2SO4 for 1 h under stirring
at room temperature. The pellet was removed by centrifugation at
15000 rpm for 20min while the supernatant was extensively dialyzed
versus 10mM sodium phosphate buffer pH 7.2 containing 20mM
MgCl2. 20mg of deoxyribonuclease I from bovine pancreas
(SigmaAldrich) were then added and the reaction was carried out for
1 h at 37 °C. The sample was subjected to a first heat treatment at 62 °C
for 10min and, after centrifugation, to a second one at 72 °C for 15min.
Denatured E. coli proteins were removed by centrifugation at
15000 rpm at 4 °C for 30min. The soluble fraction was further clarified
by disposable Sartolab® Vacuum Filters System (Polyethersulfone,
0.22 μm) using 20 g of Sartoclear Dynamics® Lab Filter Aid (Sartorius)
containing highly pure diatomaceous earth (Celpure® C300 – pharma-
ceutical grade) pre-wetted with ultrapure water. DNA removal was
performed in a single step by means of crossflow ultrafiltration using a
single Vivaflow 200 module (Sartorius) with a cutoff of 100 kDa, cou-
pled to a Masterflex L/S pump system. The same device was also used to
exchange the buffer with 20mM HEPES pH 7.4 containing 50mM
MgCl2. The feed flow rate was set to 40mL/min (transmembrane
pressure: 1.5 bar), both in concentration and diafiltration modes.
Protein purity was monitored by SDS-PAGE, using Mini-PROTEAN®
TGX Stain-Free™ Precast Gels (Biorad). DNA removal was followed by
measuring 260/280 nm ratio using a Jasco V-650 spectrophotemeter
(JASCO Deutschland).
2.3. High performance size-exclusion chromatography (HP-SEC)
HP-SEC was performed using an Agilent Infinity 1260 HPLC appa-
ratus equipped with an UV detector. Separation was carried out using
an Agilent AdvanceBio SEC 300 Å, 7.8×150mm, 2.7 μm, LC column
connected to an AdvanceBio SEC 300 Å, 7.8×50mm, 2.7 μm, LC guard
column. Isocratic analysis was carried out with 20mM HEPES buffer pH
7.4, 50mM MgCl2 as mobile phase. Flow rate was 0.7mL/min over an
elution window of 7min. HumFt elution was followed using the UV
detection at 280 nm. Protein standards were prepared in the same so-
lution as the mobile phase.
3. Results and discussion
HumFt nanocarrier has been developed in our lab combining human
H ferritin capability of recognizing TfR1 receptor and AfFtn salt
mediated association properties. As previously reported [20], HumFt
was expressed in E. coli cells under the control of an inducible promoter
and purified at lab scale level by means of a standard ferritin pur-
ification protocol involving ammonium sulfate precipitation and gel
filtration chromatography. This procedure allows to obtain about 70mg
of purified protein per liter of bacterial growth. Considering the po-
tential application of this new chimeric protein, our aim is to develop
an uncomplicated, large scale, chromatography-free purification pro-
tocol with a shorter time frame, mainly based on crossflow ultrafiltra-
tion, starting from fermented bacterial paste.
Preliminary protein expression experiments were performed at
three different IPTG concentrations and at different induction times and
temperatures. The best condition was found to be 0.5 mM IPTG at 25 °C
for 16 h. Customized large scale protein fermentation was then per-
formed using these parameters. In Fig. 1 we report the SDS-PAGE of cell
lysates. In this experimental condition, HumFt migrates as a monomer
of the expected 20 kDa molecular weight. Lane 5 shows the high level of
protein expression in the soluble fraction.
Large scale purification protocol was set up on the soluble fraction
obtained after sonication of 100 g of bacterial paste grown under fer-
mentative conditions. In this case, the amount of soluble HumFt was
even higher of the one obtained growing the bacteria in flask. The SDS-
PAGE in Fig. 2 shows the protein enrichment through the different steps
Fig. 1. Protein expression analyzed by SDS-PAGE. Lane 1: Protein Marker;
lane 2: cell lysate without induction; lane 3: BSA (2 μg); lane 4: cell lysate in-
duced by 0.5 mM IPTG at 25 °C for 16 h; lane 5: supernatant of cell lysate in-
duced by 0.5 mM IPTG at 25 °C for 16 h; lane 6: pellet of cell lysate induced by
0.5 mM IPTG at 25 °C for 16 h. The arrow corresponds to HumFt monomer
molecular weight.
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of the procedure. In the first step, 20% ammonium sulfate has been
used to precipitate some proteins, keeping HumFt in solution. A further
purification was achieved by two sequential heating steps at 62 and
78 °C. Ferritins are, generally, thermostable proteins and HumFt dis-
plays an even higher thermostability as most of its sequence belongs to
a thermophilic bacterium. These steps efficiently remove protein con-
taminants (including DNAse), but obviously fail to remove lipid mi-
celles and DNA. Lipid micelles have been easily eliminated by a filtra-
tion step using highly pure diatomaceous earth, as proved by the overall
clarification of the sample. HumFt does not interact with the diato-
maceous earth and is fully recovered after the filtration. Other con-
taminants, instead, are retained by diatomaceous earth, leading to a
further purification of the sample (Fig. 2, lane 6).
One of the major problems in the purification of recombinant fer-
ritins is represented by bacterial DNA cross-contamination. DNA has to
be removed in view of in vitro or in vivo experiments. Moreover, in the
case of HumFt, we observed that it directly affects the quaternary
structure of the protein. In the previously published protocol DNA re-
moval was achieved by DNAse treatment followed by a gel filtration on
a HiLoad 26/600 Superdex 200 pg column. This expensive and time
consuming step can indeed be avoided by the combined use of DNAse
coupled to crossflow ultrafiltration. This purification procedure has a
great advantage as it can be used in concentration and diafiltration
modes: in the first case, ferritin (480 kDa) is retained by the membrane
(100 kDa cutoff), the buffer passes through, and the protein con-
centration increases over time; in the second case, the protein is con-
centrated to remove the excess of the starting buffer, then diluted with
the new buffer and concentrated again. This process can be repeated
until the buffer is completely exchanged.
To further purify ferritin-enriched solution, 1 L sample was con-
centrated ten times at a flow of 30–40mL/min (transmembrane pres-
sure: 1.5 bar), then diluted with 1 L of washing buffer for the diafil-
tration step, keeping the recirculation rate in the range of 30–40mL/
min. During this step, DNA was removed as proven by comparing the
absorption spectra of filtered and unfiltered fractions. As shown in
Fig. 3, compared to the spectrum obtained prior the ultrafiltration step,
the retained fraction, enriched in ferritin is DNA free, displays a max-
imum absorption at 280 nm.
Once the buffer was completely exchanged by means of the diafil-
tration process, ferritin was concentrated to a final volume of 100mL
(20mg/mL). HP-SEC performed on samples before and after the dia-
lfiltration step shows that the total protein content doesn't change at all.
Ferritin is not detected in the permeate suggesting an about total pro-
tein recovery. The overall crossflow ultrafiltration process took about
1.5 h.
A further advantage is that the filtration modules can be re-
generated and reused a number of times depending on the source and
quality of the sample. In our experimental setting the filtration
performance was kept up to 10 times.
This protocol can be indeed easily extended to all recombinant
ferritins and most high molecular weight (> 100 kDa) proteins and it
can be further scaled-up connecting several crossflow filtration modules
in series and/or in parallel according to the specific needs.
One of the main challenges in large scale recombinant ferritin
purification is achieving the complete DNA removal. This is a critical
step for all proteins that are going to be used for in vivo applications and
especially for ferritins that strongly interact with nucleic acids [23]. In
the specific case of humanized ferritin, DNA traces could affect as-
sembly/disassembly equilibrium. In fact, when HumFt is purified with
conventional chromatographic methods [20], the very small amount of
DNA co-eluting with the protein does not allow a complete quaternary
assembly. HPLC-SEC analysis shows that up to 20% of ferritin is not
assembled and elutes as a dimer (Fig. 4). When DNA is completely re-
moved using the purification protocol here described, the protein elutes
as a single peak corresponding to the 24mer (Fig. 4). As HumFt has
been developed as a nanocarrier for drug delivery, the full control of the
aggregation state is of paramount importance in order to obtain a
highly efficient cargo system.
Fig. 2. Protein purification steps analyzed by SDS-PAGE. Lane 1: Protein
Marker; lane 2: sonication supernatant; lane 3: 20% ammonium sulfate super-
natant; lane 4: soluble fraction after heat treatment at 62 °C; lane 5: soluble
fraction after heat treatment at 72 °C; lane 6: sample filtered using Celpure®
C300 diatomaceous earth; lane 7: sample filtered through Vivaflow 200 module
with a cutoff of 100 kDa.
Fig. 3. DNA removal followed by UV absorption spectroscopy. Continuous
line: sample before the ultrafiltration step; dashed line: retained fraction; dotted
line: filtered fraction.
Fig. 4. HP-SEC of purified HumFt. Elution profile of HumFt followed at
280 nm. Red line: protein purified by means of HiLoad 26/600 Superdex 200 pg
column. Blue line: protein purified by crossflow ultrafiltration. HumFt 24mer
retention time: 4.22min; HumFt dimer retention time: 6.31min. (For inter-
pretation of the references to colour in this figure legend, the reader is referred
to the Web version of this article.)
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4. Conclusions
In the present paper we describe a large scale, chromatography free
protocol for the purification of a recombinant ferritin. To the best of our
knowledge, this is the first report involving the use of diatomaceous
earth filter aid coupled to crossflow ultrafiltration for the purification of
a ferritin. The current procedure can easily remove contaminant pro-
teins as well as DNA molecules in the absence of expensive and time
consuming chromatographic steps. The whole procedure takes about
one working day compared to the two/three days required for a typical
purification protocol involving chromatographic steps. In addition, the
use of crossflow ultrafiltration modules significantly reduces the overall
purification costs, as they are cheaper than basic chromatography tools
and can be extensively reused.
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